Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.

Dreyfus N, Myers JK, Badescu VO, de Frutos O, de la Puente ML, Ding C, Filla SA, Fynboe K, Gernert DL, Heinz BA, Hemrick-Luecke SK, Johnson KW, Johnson MP, López P, Love PL, Martin LJ, Masquelin T, McCoy MJ, Mendiola J, Morrow D, Muhlhauser M, Pascual G, Perun TJ, Pfeifer LA, Phebus LA, Richards SJ, Rincón JA, Seest EP, Shah J, Shaojuan J, Simmons RM, Stephenson GA, Tromiczak EG, Thompson LK, Walter MW, Weber WW, Zarrinmayeh H, Thomas CE, Joshi E, Iyengar S, Johansson AM.

ACS Med Chem Lett. 2013 May 7;4(6):560-4. doi: 10.1021/ml400049p. eCollection 2013 Jun 13.

2.

The promise of epigenetics in personalized medicine.

Weber WW.

Mol Interv. 2010 Dec;10(6):363-70. doi: 10.1124/mi.10.6.5. Review.

PMID:
21263162
3.

Pharmacogenetics: from description to prediction.

Weber WW.

Clin Lab Med. 2008 Dec;28(4):499-511. doi: 10.1016/j.cll.2008.05.002.

PMID:
19059058
4.

Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.

Franciskovich JB, Masters JJ, Weber WW, Klimkowski VJ, Chouinard M, Sipes PR, Johnson LM, Snyder DW, Chastain MK, Craft TJ, Towner RD, Gifford-Moore DS, Froelich LL, Smallwood JK, Foster RS, Smith GF, Liebeschuetz JW, Murray CW, Young SC.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6910-3. Epub 2007 Oct 24.

PMID:
17976987
5.

Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice.

Wilke RA, Musana AK, Weber WW.

Per Med. 2005 Aug;2(3):213-224. doi: 10.2217/17410541.2.3.213.

PMID:
29793264
6.

A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors.

Sheehan SM, Masters JJ, Wiley MR, Young SC, Liebeschuetz JW, Jones SD, Murray CW, Franciskovich JB, Engel DB, Weber WW, Marimuthu J, Kyle JA, Smallwood JK, Farmen MW, Smith GF.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2255-9.

PMID:
12824013
7.

Pharmacogenetic tactics and strategies: implications for paediatrics.

Weber WW.

Paediatr Drugs. 2001;3(12):863-81. Review.

PMID:
11772149
8.

The legacy of pharmacogenetics and potential applications.

Weber WW.

Mutat Res. 2001 Aug 8;479(1-2):1-18.

PMID:
11470477
9.

Effect of pharmacogenetics on medicine.

Weber WW.

Environ Mol Mutagen. 2001;37(3):179-84. Review.

10.

Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber.

Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, Weber WW.

Drug Metab Dispos. 2000 Dec;28(12):1425-32.

PMID:
11095579
11.

Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1.

de León JH, Vatsis KP, Weber WW.

Mol Pharmacol. 2000 Aug;58(2):288-99.

PMID:
10908296
12.

Populations and genetic polymorphisms.

Weber WW.

Mol Diagn. 1999 Dec;4(4):299-307. Review.

PMID:
10671640
13.

Tissue- and gender-specific expression of N-acetyltransferase 2 (Nat2*) during development of the outbred mouse strain CD-1.

Estrada L, Kanelakis KC, Levy GN, Weber WW.

Drug Metab Dispos. 2000 Feb;28(2):139-46.

PMID:
10640510
14.

Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells.

Estrada-Rodgers L, Levy GN, Weber WW.

Drug Metab Dispos. 1998 May;26(5):502-5.

PMID:
9571233
15.
16.

Induction of human prostaglandin endoperoxide H synthase-2 (PHS-2) mRNA by TCDD.

Liu Y, Levy GN, Weber WW.

Prostaglandins. 1997 Jan;53(1):1-10.

PMID:
9068062
17.

Kinetics of arylamine N-acetyltransferase in tissues from human breast cancer.

Lee JH, Chung JG, Lai JM, Levy GN, Weber WW.

Cancer Lett. 1997 Jan 1;111(1-2):39-50.

PMID:
9022126
18.

Effects of heredity on response to drugs and environmental chemicals: construction of rodent models.

Levy GN, Rodgers L, Weber WW.

Chem Res Toxicol. 1996 Dec;9(8):1215-24. Review. No abstract available.

PMID:
8951222
19.

Evidence for arylamine N-acetyltransferase in the nematode Anisakis simplex.

Chung JG, Kuo HM, Lin TH, Ho CC, Lee JH, Lai JM, Levy GN, Weber WW.

Cancer Lett. 1996 Aug 23;106(1):1-8.

PMID:
8827040
20.

Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.

Nerurkar PV, Schut HA, Anderson LM, Riggs CW, Fornwald LW, Davis CD, Snyderwine EG, Thorgeirsson SS, Weber WW, Rice JM, Levy GN.

Mol Pharmacol. 1996 May;49(5):874-81.

PMID:
8622637
21.

Kinetics of acetyl coenzyme A:arylamine N-acetyltransferase from rapid and slow acetylator frog tissues.

Ho CC, Lin TH, Lai YS, Chung JG, Levy GN, Weber WW.

Drug Metab Dispos. 1996 Feb;24(2):137-41.

PMID:
8742223
22.

Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9).

De Leon JH, Martell KJ, Vatsis KP, Weber WW.

Drug Metab Dispos. 1995 Dec;23(12):1354-61.

PMID:
8689943
23.

Activation of 2-aminofluorene by prostaglandin endoperoxide H synthase-2.

Liu Y, Levy GN, Weber WW.

Biochem Biophys Res Commun. 1995 Oct 4;215(1):346-54.

PMID:
7575612
24.

DNA adducts of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in colon, bladder, and kidney of congenic mice differing in Ah responsiveness and N-acetyltransferase genotype.

Nerurkar PV, Schut HA, Anderson LM, Riggs CW, Snyderwine EG, Thorgeirsson SS, Weber WW, Rice JM, Levy GN.

Cancer Res. 1995 Jul 15;55(14):3043-9.

25.

Nomenclature for N-acetyltransferases.

Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, et al.

Pharmacogenetics. 1995 Feb;5(1):1-17. Review.

PMID:
7773298
26.

Influence of heredity on human sensitivity to environmental chemicals.

Weber WW.

Environ Mol Mutagen. 1995;25 Suppl 26:102-14. Review.

PMID:
7789356
27.
29.

N-acetylation polymorphism in liver and pancreas of inbred rats.

Martell KJ, Weber WW.

Drug Metab Dispos. 1993 Sep-Oct;21(5):965-6. No abstract available.

PMID:
7902264
30.

Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood.

Weber WW, Vatsis KP.

Pharmacogenetics. 1993 Aug;3(4):209-12. No abstract available.

PMID:
8220441
31.

Polymorphic N-acetylation of 2-aminofluorene by cell-free colon extracts from inbred mice.

Levy GN, Martell KJ, Weber WW.

Pharmacogenetics. 1993 Apr;3(2):71-6.

PMID:
7686075
32.

Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus.

Vatsis KP, Weber WW.

Arch Biochem Biophys. 1993 Feb 15;301(1):71-6.

33.

Testosterone modulation of N-acetylation in mouse kidney.

Smolen TN, Brewer JA, Weber WW.

J Pharmacol Exp Ther. 1993 Feb;264(2):854-8.

PMID:
8437129
34.

Inhibition of human red blood cell N-acetyltransferase.

Voice RA, Manis M, Weber WW.

Drug Metab Dispos. 1993 Jan-Feb;21(1):181-3.

PMID:
8095216
35.

DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl.

Flammang TJ, Couch LH, Levy GN, Weber WW, Wise CK.

Carcinogenesis. 1992 Oct;13(10):1887-91.

PMID:
1423849
36.

Metabolic, molecular genetic and toxicological aspects of the acetylation polymorphism in inbred mice.

Levy GN, Martell KJ, DeLeon JH, Weber WW.

Pharmacogenetics. 1992 Oct;2(5):197-206. Review.

PMID:
1306119
37.

Cloned mouse N-acetyltransferases: enzymatic properties of expressed Nat-1 and Nat-2 gene products.

Martell KJ, Levy GN, Weber WW.

Mol Pharmacol. 1992 Aug;42(2):265-72.

PMID:
1513324
38.
39.

N-acetylation of aromatic amines: genetic polymorphism in inbred rat strains.

Juberg DR, Bond JT, Weber WW.

Pharmacogenetics. 1991 Oct;1(1):50-7.

PMID:
1844823
40.

Molecular genetic basis of rapid and slow acetylation in mice.

Martell KJ, Vatsis KP, Weber WW.

Mol Pharmacol. 1991 Aug;40(2):218-27.

PMID:
1875909
41.

Diverse point mutations in the human gene for polymorphic N-acetyltransferase.

Vatsis KP, Martell KJ, Weber WW.

Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6333-7.

42.

Kinetics of acetyl CoA: arylamine N-acetyltransferase from rapid and slow acetylator human liver.

Kilbane AJ, Petroff T, Weber WW.

Drug Metab Dispos. 1991 Mar-Apr;19(2):503-7.

PMID:
1676662
43.
44.
45.

Human N-acetylation genotype determination with urinary caffeine metabolites.

Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW.

Clin Pharmacol Ther. 1990 Apr;47(4):470-7. Erratum in: Clin Pharmacol Ther 1992 Oct;52(4):349.

46.

Acetylation.

Weber WW.

Birth Defects Orig Artic Ser. 1990;26(1):43-65. Review.

PMID:
2224079
47.

Polymorphic acetylation of arylamines and DNA-adduct formation.

Weber WW, Levy GN, Martell KJ.

Princess Takamatsu Symp. 1990;21:119-26. Review.

PMID:
2134671
49.

2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines.

Levy GN, Weber WW.

Carcinogenesis. 1989 Apr;10(4):705-9. Erratum in: Carcinogenesis 1989 Jul;10(7):1350.

PMID:
2702718
50.

Supplemental Content

Loading ...
Support Center